|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1
Departments of Medicine and Immunology, Duke University Medical Center, Durham, NC 27710
CD4+CD25+ regulatory T cells (TReg) play a critical role in the control of autoimmunity. However, little is known about how TReg suppress self-reactive T cells in vivo, thus limiting the development of TReg-based therapy for treating autoimmune diseases. This is in large part due to the dependency on a state of lymphopenia to demonstrate TReg-mediated suppression in vivo and the unknown Ag specificity of TReg in most experimental models. Using a nonlymphopenic model of autoimmune pneumonitis and TReg with known Ag specificity, in this study we demonstrated that these TReg can actively suppress activation of self-reactive T cells and protect mice from fatal autoimmune pneumonitis. The protection required TReg with the same Ag specificity as the self-reactive T cells and depended on IL-10 and TGF-
. These results suggest that suppression of autoimmunity by TReg in vivo consists of multiple layers of regulation and advocate for a strategy involving Ag-specific TReg for treating organ-specific autoimmunity, because they do not cause generalized immune suppression.
This article has been cited by other articles:
![]() |
P. L. Bollyky, B. A. Falk, R. P. Wu, J. H. Buckner, T. N. Wight, and G. T. Nepom Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells J. Leukoc. Biol., September 1, 2009; 86(3): 567 - 572. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Horkheimer, M. Quigley, J. Zhu, X. Huang, N. J. Chao, and Y. Yang Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation Blood, May 21, 2009; 113(21): 5330 - 5339. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Karumuthil-Melethil, N. Perez, R. Li, and C. Vasu Induction of Innate Immune Response through TLR2 and Dectin 1 Prevents Type 1 Diabetes J. Immunol., December 15, 2008; 181(12): 8323 - 8334. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hao, J. Yuan, S. Xu, M. A. Munegowda, Y. Deng, J. Gordon, Z. Xing, and J. Xiang Antigen Specificity Acquisition of Adoptive CD4+ Regulatory T Cells via Acquired Peptide-MHC Class I Complexes J. Immunol., August 15, 2008; 181(4): 2428 - 2437. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gil-Guerrero, J. Dotor, I. L. Huibregtse, N. Casares, A. B. Lopez-Vazquez, F. Rudilla, J. I. Riezu-Boj, J. Lopez-Sagaseta, J. Hermida, S. Van Deventer, et al. In Vitro and In Vivo Down-Regulation of Regulatory T Cell Activity with a Peptide Inhibitor of TGF-{beta}1 J. Immunol., July 1, 2008; 181(1): 126 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Cao, J. Zhao, Z. Lei, S. Shen, C. Liu, D. Li, J. Liu, G.-X. Shen, G.-M. Zhang, Z.-H. Feng, et al. Local Accumulation of FOXP3+ Regulatory T Cells: Evidence for an Immune Evasion Mechanism in Patients with Large Condylomata Acuminata J. Immunol., June 1, 2008; 180(11): 7681 - 7686. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Harris, J. F. Grosso, H.-R. Yen, H. Xin, M. Kortylewski, E. Albesiano, E. L. Hipkiss, D. Getnet, M. V. Goldberg, C. H. Maris, et al. Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity J. Immunol., October 1, 2007; 179(7): 4313 - 4317. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ochoa-Reparaz, C. Riccardi, A. Rynda, S. Jun, G. Callis, and D. W. Pascual Regulatory T Cell Vaccination without Autoantigen Protects against Experimental Autoimmune Encephalomyelitis J. Immunol., February 1, 2007; 178(3): 1791 - 1799. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Kobie, P. R. Shah, L. Yang, J. A. Rebhahn, D. J. Fowell, and T. R. Mosmann T Regulatory and Primed Uncommitted CD4 T Cells Express CD73, Which Suppresses Effector CD4 T Cells by Converting 5'-Adenosine Monophosphate to Adenosine J. Immunol., November 15, 2006; 177(10): 6780 - 6786. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |